The burgeoning field of metabolic disease management is witnessing a remarkable convergence of therapies. Tirzepatide , a dual GIP/GLP-1 receptor agonist , alongside Another Agent, a triple GIP/GLP-1/GCG receptor activator, are demonstrating impressive results in improving body mass and glucose control. Furthermore, the inclusion of Nicotinamide Ad